Stockreport

Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade [Financial Post (Toronto, Ontario, Canada)]

GENFIT S.A. - American Depositary Shares  (GNFT) 
PDF European Commission grants conditional marketing authorization for Iqirvo (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare li [Read more]